Head & Neck Cancers Articles

Dabrafenib/Trametinib Combo Nears 70% Response in Thyroid Cancer
Nearly 7 in 10 patients with locally advanced or metastatic BRAF V600E–mutated anaplastic thyroid cancer responded to treatment with the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib. 
Evolving Role of Surgery in Multidisciplinary Care for Head and Neck Cancer
Joseph A. Califano, MD, discusses how surgery factors into modern multidisciplinary care for patients with head and neck cancer.
Thyroid Cancer Landscape Advancing to Include Novel Surgical Techniques
Michael Bouvet, MD, highlights the evolving surgical options in the thyroid cancer field
Multidisciplinary Care Critical in Head and Neck Cancer
Assuntina G. Sacco, MD, discusses the importance of multidisciplinary care for patients with head and neck cancer. 
Study Finds Significant Survival Disparities in HPV-related Cancer
Younger patients, women, and white patients with HPV-related cancers had superior survival at 5 years, indicating that increased HPV vaccination and better access to cancer screening and treatment are likely needed to reduce survival disparities
Number of Sexual Partners, Smoking Identified as Risk Factors for Oropharyngeal Cancer
While the incidence of HPV-related oropharyngeal cancer is increasing, the risk for developing the disease remains low for most people.
 
Expert Calls for a Change in the Staging of HNSCC
Loren K. Mell, MD, explains his research for risk-stratifying patients with head and neck cancer.
Expert Differentiates Carcinogen-Induced and Virally Associated HNSCC
Kathryn A. Gold, MD, discusses HPV status and prognosis, as well recognizing risk factors of virally-associated head and neck squamous cell carcinoma.
Immunotherapy, New Targeted Approaches Explored in Thyroid Cancer
Gregory Daniels, MD, PhD, discusses the current treatment landscape of thyroid cancer and the development of immunotherapy for patients with this disease.
Role of Immunotherapy Expanding in Head and Neck Cancer
Ezra Cohen, MD, discusses the role of immunotherapy, the potential of entrectinib, and the importance of multidisciplinary teams for the treatment of patients with head and neck cancer.
Publication Bottom Border
Border Publication
x